{ "ticker": "MRNA", "cik": "0001682852", "company": "Moderna, Inc.", "business_type": "biotechnology", "schema_template": "standard (commercial-stage biotechnology): revenue split into net product sales and other revenue, operating expenses by function (cost of sales, research and development, selling, general and administrative), operating and net income or loss, per-share results; cash, investments, debt and equity; operating cash flow, capital expenditures and free cash flow. No gross profit line is reported because the company does not present one.", "reporting_currency": "USD", "converted_to_usd": false, "units": "actual US dollars (not millions); per-share figures in dollars per common share; share counts in actual shares", "units_notes_seen": { "FY2025 10-K consolidated statements of operations": "(In millions, except per share data)", "FY2025 10-K consolidated balance sheets": "(In millions, except per share data)", "FY2025 10-K consolidated statements of cash flows": "(In millions)", "FY2025 10-K Note 3 net product sales by geography and by product": "(in millions)", "Q3 2026 10-Q condensed consolidated statements of operations": "(Unaudited, in millions, except per share data)", "Q3 2026 10-Q condensed consolidated balance sheets": "(Unaudited, in millions, except per share data)", "Q3 2026 10-Q condensed consolidated statements of cash flows": "(Unaudited, in millions)", "Q3 2026 10-Q Note 3 net product sales by geography and by product": "(in millions)", "Q3 2026 10-Q Note 15 net earnings (loss) per share": "(in millions, except per share data)" }, "adjustments": { "splits_applied": [], "adr_ratio": null, "fx": "none - Moderna reports in US dollars" }, "annual": [ { "fiscal_year": 2025, "label": "FY2025", "period_start": "2025-01-01", "period_end": "2025-12-31", "period_type": "fiscal year", "source_accession": "0001682852-26-000033", "income_statement": { "net_product_sales": 1818000000, "other_revenue": 126000000, "total_revenue": 1944000000, "cost_of_sales": 868000000, "research_and_development": 3132000000, "selling_general_and_administrative": 1018000000, "total_operating_expenses": 5018000000, "operating_income": -3074000000, "interest_income": 314000000, "other_income_expense_net": -8000000, "income_before_income_taxes": -2768000000, "income_tax_expense": 54000000, "net_income": -2822000000, "basic_eps": -7.26, "diluted_eps": -7.26, "weighted_average_basic_shares": 389000000, "weighted_average_diluted_shares": 389000000, "net_product_sales_by_geography": { "united_states": 1165000000, "europe": 50000000, "rest_of_world": 603000000 }, "net_product_sales_by_product": { "covid": 1810000000, "rsv": 8000000 } }, "cash_flow": { "operating_cash_flow": -1873000000, "capex": -192000000, "investing_cash_flow": 1946000000, "financing_cash_flow": 593000000, "net_change_in_cash_and_restricted_cash": 668000000, "stock_based_compensation": 483000000, "depreciation_and_amortization": 215000000, "free_cash_flow": -2065000000 }, "balance_sheet": { "cash_and_cash_equivalents": 2595000000, "current_investments": 3204000000, "accounts_receivable_net": 184000000, "inventory": 153000000, "total_current_assets": 6544000000, "non_current_investments": 2336000000, "property_plant_and_equipment_net": 2134000000, "total_assets": 12338000000, "total_current_liabilities": 1987000000, "long_term_debt": 590000000, "total_liabilities": 3688000000, "retained_earnings": 7223000000, "total_stockholders_equity": 8650000000, "total_liabilities_and_stockholders_equity": 12338000000, "total_debt": 590000000, "common_shares_outstanding": 394000000 } }, { "fiscal_year": 2024, "label": "FY2024", "period_start": "2024-01-01", "period_end": "2024-12-31", "period_type": "fiscal year", "source_accession": "0001682852-26-000033", "income_statement": { "net_product_sales": 3109000000, "other_revenue": 127000000, "total_revenue": 3236000000, "cost_of_sales": 1464000000, "research_and_development": 4543000000, "selling_general_and_administrative": 1174000000, "total_operating_expenses": 7181000000, "operating_income": -3945000000, "interest_income": 425000000, "other_income_expense_net": -87000000, "income_before_income_taxes": -3607000000, "income_tax_expense": -46000000, "net_income": -3561000000, "basic_eps": -9.28, "diluted_eps": -9.28, "weighted_average_basic_shares": 384000000, "weighted_average_diluted_shares": 384000000, "net_product_sales_by_geography": { "united_states": 1726000000, "europe": 573000000, "rest_of_world": 810000000 }, "net_product_sales_by_product": { "covid": 3084000000, "rsv": 25000000 } }, "cash_flow": { "operating_cash_flow": -3004000000, "capex": -1051000000, "investing_cash_flow": 1949000000, "financing_cash_flow": 56000000, "net_change_in_cash_and_restricted_cash": -999000000, "stock_based_compensation": 429000000, "depreciation_and_amortization": 189000000, "free_cash_flow": -4055000000 }, "balance_sheet": { "cash_and_cash_equivalents": 1927000000, "current_investments": 5098000000, "accounts_receivable_net": 358000000, "inventory": 117000000, "total_current_assets": 8099000000, "non_current_investments": 2494000000, "property_plant_and_equipment_net": 2196000000, "total_assets": 14142000000, "total_current_liabilities": 2206000000, "long_term_debt": 0, "total_liabilities": 3241000000, "retained_earnings": 10045000000, "total_stockholders_equity": 10901000000, "total_liabilities_and_stockholders_equity": 14142000000, "total_debt": 0, "common_shares_outstanding": 386000000 } }, { "fiscal_year": 2023, "label": "FY2023", "period_start": "2023-01-01", "period_end": "2023-12-31", "period_type": "fiscal year", "source_accession": "0001682852-26-000033", "income_statement": { "net_product_sales": 6671000000, "other_revenue": 177000000, "total_revenue": 6848000000, "cost_of_sales": 4693000000, "research_and_development": 4845000000, "selling_general_and_administrative": 1549000000, "total_operating_expenses": 11087000000, "operating_income": -4239000000, "interest_income": 421000000, "other_income_expense_net": -124000000, "income_before_income_taxes": -3942000000, "income_tax_expense": 772000000, "net_income": -4714000000, "basic_eps": -12.33, "diluted_eps": -12.33, "weighted_average_basic_shares": 382000000, "weighted_average_diluted_shares": 382000000, "net_product_sales_by_geography": { "united_states": 1720000000, "europe": 1353000000, "rest_of_world": 3598000000 }, "net_product_sales_by_product": { "covid": 6671000000, "rsv": 0 } }, "cash_flow": { "operating_cash_flow": -3118000000, "capex": -707000000, "investing_cash_flow": 4206000000, "financing_cash_flow": -1377000000, "net_change_in_cash_and_restricted_cash": -289000000, "stock_based_compensation": 305000000, "depreciation_and_amortization": 621000000, "free_cash_flow": -3825000000 } } ], "quarterly": [ { "fiscal_year": 2026, "fiscal_quarter": 3, "label": "Q3 FY2026", "period_start": "2026-07-01", "period_end": "2026-09-30", "period_type": "three months", "source_accession": "0001682852-26-000197", "income_statement": { "net_product_sales": 1273000000, "other_revenue": 40000000, "total_revenue": 1313000000, "cost_of_sales": 318000000, "research_and_development": 583000000, "selling_general_and_administrative": 282000000, "total_operating_expenses": 1183000000, "operating_income": 130000000, "interest_income": 62000000, "other_income_expense_net": -21000000, "income_before_income_taxes": 171000000, "income_tax_expense": 9000000, "net_income": 162000000, "basic_eps": 0.4, "diluted_eps": 0.38, "weighted_average_basic_shares": 401000000, "weighted_average_diluted_shares": 430000000, "net_income_for_diluted_eps": 163000000, "net_product_sales_by_geography": { "united_states": 771000000, "europe": 314000000, "rest_of_world": 188000000 }, "net_product_sales_by_product": { "covid": 1244000000, "rsv": 29000000 } }, "balance_sheet": { "cash_and_cash_equivalents": 1195000000, "current_investments": 3976000000, "accounts_receivable_net": 1367000000, "inventory": 313000000, "total_current_assets": 7344000000, "non_current_investments": 2805000000, "property_plant_and_equipment_net": 2036000000, "total_assets": 13468000000, "total_current_liabilities": 2028000000, "long_term_debt": 591000000, "convertible_notes": 2958000000, "total_liabilities": 6631000000, "retained_earnings": 5260000000, "total_stockholders_equity": 6837000000, "total_liabilities_and_stockholders_equity": 13468000000, "total_debt": 3549000000, "common_shares_outstanding": 404000000 } }, { "fiscal_year": 2025, "fiscal_quarter": 3, "label": "Q3 FY2025", "period_start": "2025-07-01", "period_end": "2025-09-30", "period_type": "three months", "source_accession": "0001682852-26-000197", "income_statement": { "net_product_sales": 973000000, "other_revenue": 43000000, "total_revenue": 1016000000, "cost_of_sales": 207000000, "research_and_development": 801000000, "selling_general_and_administrative": 268000000, "total_operating_expenses": 1276000000, "operating_income": -260000000, "interest_income": 73000000, "other_income_expense_net": 0, "income_before_income_taxes": -187000000, "income_tax_expense": 13000000, "net_income": -200000000, "basic_eps": -0.51, "diluted_eps": -0.51, "weighted_average_basic_shares": 390000000, "weighted_average_diluted_shares": 390000000, "net_income_for_diluted_eps": -200000000, "net_product_sales_by_geography": { "united_states": 782000000, "europe": 16000000, "rest_of_world": 175000000 }, "net_product_sales_by_product": { "covid": 971000000, "rsv": 2000000 } } } ], "year_to_date": { "fiscal_year": 2026, "label": "9M FY2026", "period_start": "2026-01-01", "period_end": "2026-09-30", "period_type": "nine months", "source_accession": "0001682852-26-000197", "prior_year_comparative": { "fiscal_year": 2025, "label": "9M FY2025", "period_start": "2025-01-01", "period_end": "2025-09-30", "period_type": "nine months", "source_accession": "0001682852-26-000197", "income_statement": { "net_product_sales": 1172000000, "other_revenue": 94000000, "total_revenue": 1266000000, "cost_of_sales": 416000000, "research_and_development": 2357000000, "selling_general_and_administrative": 710000000, "total_operating_expenses": 3483000000, "operating_income": -2217000000, "interest_income": 244000000, "other_income_expense_net": 4000000, "income_before_income_taxes": -1969000000, "income_tax_expense": 27000000, "net_income": -1996000000, "basic_eps": -5.15, "diluted_eps": -5.15, "weighted_average_basic_shares": 388000000, "weighted_average_diluted_shares": 388000000, "net_income_for_diluted_eps": -1996000000, "net_product_sales_by_geography": { "united_states": 901000000, "europe": 16000000, "rest_of_world": 255000000 }, "net_product_sales_by_product": { "covid": 1168000000, "rsv": 4000000 } }, "cash_flow": { "operating_cash_flow": -2803000000, "capex": -153000000, "investing_cash_flow": 1994000000, "financing_cash_flow": 12000000, "net_change_in_cash_and_restricted_cash": -795000000, "stock_based_compensation": 370000000, "depreciation_and_amortization": 148000000, "proceeds_from_issuance_of_convertible_notes": 0, "free_cash_flow": -2956000000 } }, "income_statement": { "net_product_sales": 1719000000, "other_revenue": 128000000, "total_revenue": 1847000000, "cost_of_sales": 1366000000, "research_and_development": 1883000000, "selling_general_and_administrative": 671000000, "total_operating_expenses": 3920000000, "operating_income": -2073000000, "interest_income": 201000000, "other_income_expense_net": -58000000, "income_before_income_taxes": -1930000000, "income_tax_expense": 33000000, "net_income": -1963000000, "basic_eps": -4.93, "diluted_eps": -4.93, "weighted_average_basic_shares": 398000000, "weighted_average_diluted_shares": 398000000, "net_income_for_diluted_eps": -1963000000, "net_product_sales_by_geography": { "united_states": 914000000, "europe": 569000000, "rest_of_world": 236000000 }, "net_product_sales_by_product": { "covid": 1680000000, "rsv": 39000000 } }, "cash_flow": { "operating_cash_flow": -2715000000, "capex": -146000000, "investing_cash_flow": -1462000000, "financing_cash_flow": 2776000000, "net_change_in_cash_and_restricted_cash": -1401000000, "stock_based_compensation": 351000000, "depreciation_and_amortization": 190000000, "proceeds_from_issuance_of_convertible_notes": 3000000000, "free_cash_flow": -2861000000 } }, "trailing_twelve_months": { "label": "TTM ended Q3 FY2026", "period_start": "2025-10-01", "period_end": "2026-09-30", "period_type": "trailing twelve months", "source_accession": "0001682852-26-000197", "derived_from": [ "0001682852-26-000033", "0001682852-26-000197" ], "derivation": "FY2025 (10-K) plus nine months ended September 30, 2026 less nine months ended September 30, 2025 (10-Q)", "income_statement": { "net_product_sales": 2365000000, "other_revenue": 160000000, "total_revenue": 2525000000, "cost_of_sales": 1818000000, "research_and_development": 2658000000, "selling_general_and_administrative": 979000000, "total_operating_expenses": 5455000000, "operating_income": -2930000000, "interest_income": 271000000, "net_income": -2789000000 }, "cash_flow": { "operating_cash_flow": -1785000000, "capex": -185000000, "free_cash_flow": -1970000000 } }, "notes": [ "Template: a commercial-stage biotechnology company with product sales of its COVID and RSV vaccines. The income statement is shown as Moderna presents it, with operating expenses by function; Moderna does not report a gross profit line, so none is shown.", "Annual figures for FY2025, FY2024 and FY2023 come from the FY2025 Form 10-K (accession 0001682852-26-000033). That filing presents balance sheets only at December 31, 2025 and December 31, 2024, so FY2023 carries no balance sheet.", "Quarterly figures for the three months ended September 30, 2026 and September 30, 2025, and the nine-month figures in year_to_date, come from the Q3 2026 Form 10-Q (accession 0001682852-26-000197). The 10-Q presents balance sheets at September 30, 2026 and December 31, 2025 only, so Q3 FY2025 carries no balance sheet; the December 31, 2025 column in the 10-Q matches the FY2025 10-K balance sheet line for line.", "The 10-Q's cash flow statement covers only the nine-month periods, so cash flow figures appear in year_to_date and its prior-year comparative, not in the quarterly entries.", "total_debt is the term loan carried as long-term debt ($591 million at September 30, 2026 and $590 million at December 31, 2025, against $600 million of principal) plus the convertible notes ($2,958 million at September 30, 2026). It excludes operating and finance lease liabilities. Moderna had no long-term debt at December 31, 2024.", "The convertible notes are $3.0 billion of 0.00% Convertible Senior Notes due 2032, issued September 1, 2026. Moderna paid $329 million for related capped call transactions, recorded as a reduction of additional paid-in capital.", "capex is purchases of property, plant and equipment as printed in the cash flow statement (shown as a negative outflow). free_cash_flow is operating cash flow less capex, computed here; it is not a measure Moderna reports.", "Diluted EPS for the third quarter of 2026 ($0.38) uses net income of $163 million (net income of $162 million plus $1 million of after-tax interest expense on the convertible notes) over 430 million diluted shares (401 million basic plus 24 million from equity awards and 5 million from the convertible notes), as shown in Note 15 of the 10-Q. In every loss period basic and diluted EPS are the same.", "Share counts are printed in millions in the filings, so weighted-average and outstanding share counts here are rounded to the nearest million. The 10-Q cover reports 404,620,975 shares outstanding as of October 30, 2026.", "income_tax_expense is the provision for income taxes; FY2024 shows a tax benefit of $46 million (negative).", "The trailing-twelve-month view is FY2025 plus the nine months ended September 30, 2026 less the nine months ended September 30, 2025.", "Net product sales by product: COVID includes Spikevax and mNEXSPIKE. The 10-Q describes net product sales of mFLUSIVA, launched in September 2026, as immaterial for the quarter, and its product table shows only COVID and RSV.", "Moderna's only recorded share split (a reverse split in 2018) predates every period here, so no split adjustment applies. Moderna reports in US dollars and its common stock trades directly on Nasdaq, so no currency or ADS conversion applies." ], "uncertainties": [ "Three-month cash flow figures for the third quarter of 2026 and 2025 are not shown: the 10-Q and the accompanying earnings release print cash flows for the nine-month periods only.", "Other (expense) income, net for the third quarter of 2025 is printed as a dash and recorded as zero; the 10-Q's discussion describes it as an immaterial amount." ], "headline": { "period": "Q3 FY2026", "period_end_words": "September 30, 2026", "metrics": [ { "label": "Revenue", "format": "usd", "value": 1313000000, "text": "$1.31 billion", "exact": "$1,313,000,000", "compact": "$1.31B", "abs": "$1.31 billion", "prior_value": 1016000000, "prior": "$1.02 billion", "priorabs": "$1.02 billion", "yoy": "up 29.2%", "source": { "array": "quarterly", "field": "income_statement.total_revenue", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001682852-26-000197", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001682852-26-000197", "gap_days": 365 } }, { "label": "Net income", "format": "usd", "value": 162000000, "text": "$162 million", "exact": "$162,000,000", "compact": "$162.00M", "abs": "$162 million", "prior_value": -200000000, "prior": "-$200 million", "priorabs": "$200 million", "yoy": "swung from -$200 million", "source": { "array": "quarterly", "field": "income_statement.net_income", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001682852-26-000197", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001682852-26-000197", "gap_days": 365 } }, { "label": "Diluted EPS", "format": "eps", "value": 0.38, "text": "$0.38", "exact": "$0.38", "compact": "$0.38", "abs": "$0.38", "prior_value": -0.51, "prior": "-$0.51", "priorabs": "$0.51", "yoy": "swung from -$0.51", "source": { "array": "quarterly", "field": "income_statement.diluted_eps", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001682852-26-000197", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001682852-26-000197", "gap_days": 365 } }, { "label": "Europe net product sales", "format": "usd", "value": 314000000, "text": "$314 million", "exact": "$314,000,000", "compact": "$314.00M", "abs": "$314 million", "prior_value": 16000000, "prior": "$16 million", "priorabs": "$16 million", "yoy": "up 1,862.5%", "source": { "array": "quarterly", "field": "income_statement.net_product_sales_by_geography.europe", "index": 0, "period_label": "Q3 FY2026", "period_end": "2026-09-30", "period_start": "2026-07-01", "span_days": 91, "source_accession": "0001682852-26-000197", "prior_index": 1, "prior_period_label": "Q3 FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-07-01", "prior_span_days": 91, "prior_source_accession": "0001682852-26-000197", "gap_days": 365 } }, { "label": "Nine-month net income", "format": "usd", "value": -1963000000, "text": "-$1.96 billion", "exact": "-$1,963,000,000", "compact": "-$1.96B", "abs": "$1.96 billion", "prior_value": -1996000000, "prior": "-$2.00 billion", "priorabs": "$2.00 billion", "yoy": "up 1.7%", "source": { "array": "year_to_date", "field": "income_statement.net_income", "index": null, "period_label": "9M FY2026", "period_end": "2026-09-30", "period_start": "2026-01-01", "span_days": 272, "source_accession": "0001682852-26-000197", "prior_array": "year_to_date.prior_year_comparative", "prior_index": null, "prior_period_label": "9M FY2025", "prior_period_end": "2025-09-30", "prior_period_start": "2025-01-01", "prior_span_days": 272, "prior_source_accession": "0001682852-26-000197", "gap_days": 365 } } ], "summary": "Moderna reported $1.31 billion in revenue for Q3 FY2026, the quarter ended September 30, 2026, up 29.2% from a year earlier, and net income of $162 million, or $0.38 per diluted share, against a net loss of $200 million in the same quarter a year earlier. Sales rose mainly on COVID vaccine sales in international markets under long-term government partnerships, with net product sales in Europe rising to $314 million from $16 million, and research and development spending fell. Moderna's vaccine sales are concentrated in the fall, and for the nine months ended September 30, 2026 it posted a net loss of $1.96 billion, against $2.00 billion a year earlier, a period that included a charge for its patent settlement with Arbutus and Genevant.", "qa": [ { "q": "How much revenue did Moderna report in Q3 FY2026?", "a": "Moderna reported $1.31 billion in total revenue for Q3 FY2026, the quarter ended September 30, 2026. That is up 29.2% from $1.02 billion in the same quarter a year earlier." }, { "q": "Was Moderna profitable in Q3 FY2026?", "a": "Yes. Moderna reported net income of $162 million for Q3 FY2026, the quarter ended September 30, 2026, or $0.38 per diluted share, against a net loss of $200 million, or $0.51 per share, in the same quarter a year earlier." }, { "q": "Why did Moderna's sales rise in Q3 FY2026?", "a": "Moderna's sales rose in Q3 FY2026 mainly on COVID vaccine sales in international markets under its long-term government partnerships. Net product sales in Europe were $314 million in the quarter ended September 30, 2026, against $16 million a year earlier." }, { "q": "Is Moderna profitable in 2026 so far?", "a": "No. Despite a profitable third quarter, Moderna posted a net loss of $1.96 billion for the nine months ended September 30, 2026, against a net loss of $2.00 billion a year earlier. The 2026 period included a charge for its patent settlement with Arbutus and Genevant." } ] }, "company_details": { "Name": "Moderna, Inc.", "Ticker": "MRNA", "CIK": "0001682852", "Exchange": "Nasdaq", "State": "Massachusetts", "Incorporation": "Delaware", "SIC": "2836", "Office": "Life Sciences", "Industry": "Biological Products, (No Diagnostic Substances)" }, "next_filing": { "predicted_date": "2027-02-19", "predicted_type": "10-K" }, "fiscal_period": { "fiscal_year": 2026, "fiscal_period": "Q3", "tag": "FY26Q3", "period_end": "2026-09-30", "form": "10-Q", "accession": "0001682852-26-000197", "fiscal_year_end": "1231", "source": "facts" }, "source_filings": [ { "role": "annual", "current": false, "form": "10-K", "fiscal_year": 2025, "fiscal_period": "FY", "tag": "FY25", "period_end": "2025-12-31", "filed": "2026-02-20", "accession": "0001682852-26-000033", "url": "https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm", "source": "reported" }, { "role": "quarterly", "current": true, "form": "10-Q", "fiscal_year": 2026, "fiscal_period": "Q3", "tag": "FY26Q3", "period_end": "2026-09-30", "filed": "2026-11-06", "accession": "0001682852-26-000197", "url": "https://www.sec.gov/Archives/edgar/data/1682852/000168285226000197/mrna-20260930.htm", "source": "facts" } ], "figure_sources": { "about": "Where each figure in this file is printed in its SEC filing. This block mirrors the paths of the figures: figure_sources.annual[0].income_statement.net_income is the source of annual[0].income_statement.net_income. Each entry reads '#', and the link is documents[] + '#': it opens the filing at the line that prints that number. A figure with no entry is not printed in a tagged filing, either because it was calculated (margins, free cash flow, trailing twelve months, a quarter derived by subtraction) or because it comes from an untagged earnings release.", "documents": { "d1": "https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm", "d2": "https://www.sec.gov/Archives/edgar/data/1682852/000168285226000197/mrna-20260930.htm" }, "annual": [ { "period_end": "2025-12-31", "income_statement": { "net_product_sales": "d1#f-129", "other_revenue": "d1#f-132", "total_revenue": "d1#f-135", "cost_of_sales": "d1#f-138", "research_and_development": "d1#f-141", "selling_general_and_administrative": "d1#f-144", "total_operating_expenses": "d1#f-147", "operating_income": "d1#f-150", "interest_income": "d1#f-153", "other_income_expense_net": "d1#f-156", "income_before_income_taxes": "d1#f-159", "income_tax_expense": "d1#f-162", "net_income": "d1#f-165", "diluted_eps": "d1#f-168", "weighted_average_basic_shares": "d1#f-174", "weighted_average_diluted_shares": "d1#f-174", "net_product_sales_by_geography": { "united_states": "d1#f-500", "europe": "d1#f-503", "rest_of_world": "d1#f-506" }, "net_product_sales_by_product": { "covid": "d1#f-513" } }, "cash_flow": { "operating_cash_flow": "d1#f-333", "capex": "d1#f-345", "investing_cash_flow": "d1#f-357", "financing_cash_flow": "d1#f-375", "net_change_in_cash_and_restricted_cash": "d1#f-381", "stock_based_compensation": "d1#f-291", "depreciation_and_amortization": "d1#f-294" }, "balance_sheet": { "cash_and_cash_equivalents": "d1#f-53", "current_investments": "d1#f-55", "accounts_receivable_net": "d1#f-912", "inventory": "d1#f-59", "total_current_assets": "d1#f-63", "property_plant_and_equipment_net": "d1#f-67", "total_assets": "d1#f-73", "total_current_liabilities": "d1#f-83", "long_term_debt": "d1#f-91", "total_liabilities": "d1#f-95", "retained_earnings": "d1#f-123", "total_stockholders_equity": "d1#f-125", "total_liabilities_and_stockholders_equity": "d1#f-127", "total_debt": "d1#f-91", "common_shares_outstanding": "d1#f-113" } }, { "period_end": "2024-12-31", "income_statement": { "net_product_sales": "d1#f-130", "other_revenue": "d1#f-133", "total_revenue": "d1#f-136", "cost_of_sales": "d1#f-139", "research_and_development": "d1#f-142", "selling_general_and_administrative": "d1#f-145", "total_operating_expenses": "d1#f-148", "operating_income": "d1#f-151", "interest_income": "d1#f-154", "other_income_expense_net": "d1#f-157", "income_before_income_taxes": "d1#f-160", "income_tax_expense": "d1#f-163", "net_income": "d1#f-166", "diluted_eps": "d1#f-170", "weighted_average_basic_shares": "d1#f-176", "weighted_average_diluted_shares": "d1#f-176", "net_product_sales_by_geography": { "united_states": "d1#f-501", "europe": "d1#f-504", "rest_of_world": "d1#f-507" }, "net_product_sales_by_product": { "covid": "d1#f-1398", "rsv": "d1#f-517" } }, "cash_flow": { "operating_cash_flow": "d1#f-334", "capex": "d1#f-346", "investing_cash_flow": "d1#f-358", "financing_cash_flow": "d1#f-376", "net_change_in_cash_and_restricted_cash": "d1#f-382", "stock_based_compensation": "d1#f-292", "depreciation_and_amortization": "d1#f-295" }, "balance_sheet": { "cash_and_cash_equivalents": "d1#f-54", "current_investments": "d1#f-56", "accounts_receivable_net": "d1#f-913", "inventory": "d1#f-60", "total_current_assets": "d1#f-64", "property_plant_and_equipment_net": "d1#f-68", "total_assets": "d1#f-74", "total_current_liabilities": "d1#f-84", "total_liabilities": "d1#f-96", "retained_earnings": "d1#f-124", "total_stockholders_equity": "d1#f-126", "total_liabilities_and_stockholders_equity": "d1#f-128", "common_shares_outstanding": "d1#f-115" } }, { "period_end": "2023-12-31", "income_statement": { "net_product_sales": "d1#f-131", "other_revenue": "d1#f-134", "total_revenue": "d1#f-137", "cost_of_sales": "d1#f-140", "research_and_development": "d1#f-143", "selling_general_and_administrative": "d1#f-146", "total_operating_expenses": "d1#f-149", "operating_income": "d1#f-152", "interest_income": "d1#f-155", "other_income_expense_net": "d1#f-158", "income_before_income_taxes": "d1#f-161", "income_tax_expense": "d1#f-164", "net_income": "d1#f-167", "basic_eps": "d1#f-172", "diluted_eps": "d1#f-1466", "weighted_average_basic_shares": "d1#f-178", "weighted_average_diluted_shares": "d1#f-178", "net_product_sales_by_geography": { "united_states": "d1#f-502", "europe": "d1#f-505", "rest_of_world": "d1#f-1487" }, "net_product_sales_by_product": { "covid": "d1#f-515" } }, "cash_flow": { "operating_cash_flow": "d1#f-335", "capex": "d1#f-347", "investing_cash_flow": "d1#f-359", "financing_cash_flow": "d1#f-377", "net_change_in_cash_and_restricted_cash": "d1#f-383", "stock_based_compensation": "d1#f-293", "depreciation_and_amortization": "d1#f-296" } } ], "quarterly": [ { "period_end": "2026-09-30", "income_statement": { "net_product_sales": "d2#f-108", "other_revenue": "d2#f-828", "total_revenue": "d2#f-116", "cost_of_sales": "d2#f-120", "research_and_development": "d2#f-124", "selling_general_and_administrative": "d2#f-128", "total_operating_expenses": "d2#f-132", "operating_income": "d2#f-136", "interest_income": "d2#f-140", "other_income_expense_net": "d2#f-144", "income_before_income_taxes": "d2#f-148", "income_tax_expense": "d2#f-152", "net_income": "d2#f-156", "basic_eps": "d2#f-160", "diluted_eps": "d2#f-164", "weighted_average_basic_shares": "d2#f-168", "weighted_average_diluted_shares": "d2#f-172", "net_income_for_diluted_eps": "d2#f-1108", "net_product_sales_by_geography": { "united_states": "d2#f-426", "europe": "d2#f-430", "rest_of_world": "d2#f-434" }, "net_product_sales_by_product": { "covid": "d2#f-443", "rsv": "d2#f-447" } }, "balance_sheet": { "cash_and_cash_equivalents": "d2#f-30", "current_investments": "d2#f-32", "accounts_receivable_net": "d2#f-815", "inventory": "d2#f-36", "total_current_assets": "d2#f-40", "property_plant_and_equipment_net": "d2#f-44", "total_assets": "d2#f-50", "total_current_liabilities": "d2#f-60", "long_term_debt": "d2#f-68", "convertible_notes": "d2#f-70", "total_liabilities": "d2#f-74", "retained_earnings": "d2#f-102", "total_stockholders_equity": "d2#f-104", "total_liabilities_and_stockholders_equity": "d2#f-106", "common_shares_outstanding": "d2#f-92" } }, { "period_end": "2025-09-30", "income_statement": { "net_product_sales": "d2#f-109", "other_revenue": "d2#f-1037", "total_revenue": "d2#f-117", "cost_of_sales": "d2#f-121", "research_and_development": "d2#f-125", "selling_general_and_administrative": "d2#f-129", "total_operating_expenses": "d2#f-133", "operating_income": "d2#f-137", "interest_income": "d2#f-141", "income_before_income_taxes": "d2#f-149", "income_tax_expense": "d2#f-153", "net_income": "d2#f-157", "basic_eps": "d2#f-161", "diluted_eps": "d2#f-165", "weighted_average_basic_shares": "d2#f-169", "weighted_average_diluted_shares": "d2#f-173", "net_income_for_diluted_eps": "d2#f-1109", "net_product_sales_by_geography": { "united_states": "d2#f-427", "europe": "d2#f-431", "rest_of_world": "d2#f-435" }, "net_product_sales_by_product": { "covid": "d2#f-444" } } } ], "year_to_date": { "income_statement": { "net_product_sales": "d2#f-110", "other_revenue": "d2#f-114", "total_revenue": "d2#f-118", "cost_of_sales": "d2#f-122", "research_and_development": "d2#f-126", "selling_general_and_administrative": "d2#f-130", "total_operating_expenses": "d2#f-134", "operating_income": "d2#f-138", "interest_income": "d2#f-142", "other_income_expense_net": "d2#f-146", "income_before_income_taxes": "d2#f-150", "income_tax_expense": "d2#f-154", "net_income": "d2#f-158", "basic_eps": "d2#f-162", "diluted_eps": "d2#f-166", "weighted_average_basic_shares": "d2#f-170", "weighted_average_diluted_shares": "d2#f-174", "net_income_for_diluted_eps": "d2#f-1110", "net_product_sales_by_geography": { "united_states": "d2#f-428", "europe": "d2#f-432", "rest_of_world": "d2#f-436" }, "net_product_sales_by_product": { "covid": "d2#f-445", "rsv": "d2#f-832" } }, "cash_flow": { "operating_cash_flow": "d2#f-338", "capex": "d2#f-346", "investing_cash_flow": "d2#f-350", "financing_cash_flow": "d2#f-364", "net_change_in_cash_and_restricted_cash": "d2#f-368", "stock_based_compensation": "d2#f-310", "depreciation_and_amortization": "d2#f-312", "proceeds_from_issuance_of_convertible_notes": "d2#f-352" }, "prior_year_comparative": { "income_statement": { "net_product_sales": "d2#f-111", "other_revenue": "d2#f-115", "total_revenue": "d2#f-119", "cost_of_sales": "d2#f-123", "research_and_development": "d2#f-127", "selling_general_and_administrative": "d2#f-131", "total_operating_expenses": "d2#f-135", "operating_income": "d2#f-139", "interest_income": "d2#f-143", "other_income_expense_net": "d2#f-147", "income_before_income_taxes": "d2#f-151", "income_tax_expense": "d2#f-155", "net_income": "d2#f-159", "basic_eps": "d2#f-163", "diluted_eps": "d2#f-167", "weighted_average_basic_shares": "d2#f-171", "weighted_average_diluted_shares": "d2#f-175", "net_income_for_diluted_eps": "d2#f-1111", "net_product_sales_by_geography": { "united_states": "d2#f-429", "europe": "d2#f-433", "rest_of_world": "d2#f-437" }, "net_product_sales_by_product": { "covid": "d2#f-446", "rsv": "d2#f-147" } }, "cash_flow": { "operating_cash_flow": "d2#f-339", "capex": "d2#f-347", "investing_cash_flow": "d2#f-351", "financing_cash_flow": "d2#f-365", "net_change_in_cash_and_restricted_cash": "d2#f-369", "stock_based_compensation": "d2#f-311", "depreciation_and_amortization": "d2#f-313" } } } } }